Goldman Sachs Call 115 MRK 17.01..../ DE000GJ7K6S2 /
1/9/2025 10:24:19 AM | Chg.-0.001 | Bid4:31:24 PM | Ask4:31:24 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.021EUR | -4.55% | - Bid Size: - |
- Ask Size: - |
Merck and Co Inc | 115.00 USD | 1/17/2025 | Call |
GlobeNewswire
7/31/2024
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire
7/17/2024
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
6/11/2024
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
6/6/2024
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
5/28/2024
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
5/23/2024
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire
5/16/2024
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/14/2024
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
5/8/2024
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
4/24/2024
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
4/15/2024
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness